EUVIMEDEUVIMED entdecken
Crossref

A Comparative Study of the Efficacy of Atorvastatin Vs Rosuvastatin in Patients with Dyslipidemia Attending Tertiary Care Teaching Hospital

Ajit Kishor, Neha Fatima, Raj Narayan Seth, Keshav Kumar Sinha

International Journal of Current Pharmaceutical Review and Research · 30.04.2026 · 18 (04)

DOI: 10.25258/ijcpr.18.4.197 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Current Pharmaceutical Review and Research, online erschienen am 30.04.2026. Verfasst von Ajit Kishor und 3 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Dyslipidemia is a significant and modifiable risk factor for cardiovascular diseases with high low-density lipoprotein (LDL), elevated triglycerides (TG) levels, or low high-density lipoprotein (HDL). It is involved in atherosclerosis, coronary heart disease and stroke. Statins remain the first line pharmacological treatment, as they block HMG-CoA reductase resulting in decreased hepatic cholesterol synthesis and LDL receptor activity. Atorvastatin and Rosuvastatin are the most commonly prescribed statins for lipid control.

Methods

This prospective, randomised, open-label comparative study carried out over 1 year (December 2021-December 2022). A hundred patients with dyslipidaemia were randomly divided into two groups (n=50). Group A was given Atorvastatin 20 mg once daily, while Group B received Rosuvastatin 10 mg once daily for a period of 12 weeks. Fasting lipids were measured at baseline and after 12 weeks. Values of p < 0.05 were considered statistically significant.

Results

There was a significant improvement of lipids in both groups (p < 0.001). Reduction of LDL was by 17.78% with Atorvastatin and 19.26% with Rosuvastatin respectively. HDL was 5.54% higher and 9.13% respectively. The levels of TG were reduced by 11.50% and 13.96%. Rosuvastatin had a marginally superior effect on lipid reduction.

Conclusion

Both Atorvastatin and Rosuvastatin are effective with good tolerability in treatment of dyslipidemia. Rosuvastatin showed small advantage in LDL lowering and HDL improvements compared to Atorvastatin, which remains a cost-effective option for everyday clinical application.

Zitieren

APA

Kishor, A., Fatima, N., Seth, R. N., & Sinha, K. K. (2026). A Comparative Study of the Efficacy of Atorvastatin Vs Rosuvastatin in Patients with Dyslipidemia Attending Tertiary Care Teaching Hospital. International Journal of Current Pharmaceutical Review and Research, 18(04). https://doi.org/10.25258/ijcpr.18.4.197

Vancouver

Kishor A, Fatima N, Seth RN, Sinha KK. A Comparative Study of the Efficacy of Atorvastatin Vs Rosuvastatin in Patients with Dyslipidemia Attending Tertiary Care Teaching Hospital. International Journal of Current Pharmaceutical Review and Research. 2026;18(04). doi:10.25258/ijcpr.18.4.197

BibTeX
@article{Kishor2026,
  author = {Kishor, Ajit and Fatima, Neha and Seth, Raj Narayan and Sinha, Keshav Kumar},
  title = {A Comparative Study of the Efficacy of Atorvastatin Vs Rosuvastatin in Patients with Dyslipidemia Attending Tertiary Care Teaching Hospital},
  journal = {International Journal of Current Pharmaceutical Review and Research},
  year = {2026},
  volume = {18},
  number = {04},
  doi = {10.25258/ijcpr.18.4.197}
}
Kostenlos starten →